Beryllium Exposure Testing Health effects assessed for DOE employees exposed to airborne beryllium

To help protect workers, the Oak Ridge Institute for Science and Education maintains a comprehensive beryllium exposure studies and testing program for the U.S. Department of Energy. It assesses the health effects to workers who have been exposed to airborne beryllium.

Beryllium is used in many industries, including aerospace, defense and nuclear weapons production. During manufacturing activities, workers may have inhaled beryllium as dust or fumes, and some individuals may have become sensitized. This sensitization can be an early indicator of chronic beryllium disease (CBD), formerly known as berylliosis.

CBD leads to the development of small, inflammatory nodules in the lungs. These nodules, called granulomas, cause the patient to cough and experience shortness of breath. Chest pains, joint aches, weight loss and fever are other symptoms.

Workers can benefit from the beryllium lymphocyte proliferation test (BeLPT), a key diagnostic tool. The blood test determines beryllium sensitization and helps identify workers who may be at greater risk for developing CBD. It is recommended for workers who have been—or potentially could have been—exposed to beryllium.

Captured in the Beryllium-Associated Worker Registry, ORISE also collects information from 27 reporting DOE sites on nearly 32,000 workers to assist DOE in the analysis of this health surveillance data focusing on predictive indicators and risk management.

The ORISE beryllium testing program encompasses:

Lab is one of three in U.S. certified to test for sensitization to beryllium

ORISE is a research leader in beryllium studies and is one of three laboratories in the United States that performs the beryllium lymphocyte proliferation test (BeLPT).

ORISE conducted early research on the development of beryllium sensitization and diseases and began performing beryllium exposure testing in 1991. The ORISE Beryllium Testing Laboratory adheres to the regulations and federal standards found in the Clinical Laboratory Improvement Amendments of 1988 (CLIA ’88) and is certified by the College of American Pathologists (CAP). See CAP accreditation #7214435.

A complex medical test, the BeLPT is the primary diagnostic test to determine if workers exposed to beryllium have become sensitized to it. The sensitization can be an indicator of chronic beryllium disease (CBD), a treatable but incurable disease. Workers may have been exposed to beryllium as it is a metal and alloy used in various manufacturing processes.

The laboratory performs the BeLPT according to the U.S. Department of Energy specification DOE-SPEC-1142-2019. Lymphocytes are separated from whole blood, challenged with a beryllium solution, and allowed to incubate for five and seven days. Following the incubation, the cell growth is stopped, and the proliferation rate is calculated. If the cells in the beryllium solution have multiplied significantly faster than the controls, the test is considered to be “abnormal” indicating beryllium sensitization. View the ORISE Beryllium Guide to Lab Results for more details on testing results.

Beryllium Lymphocyte Proliferation Test (BeLPT) Process

A blood test, called a Lymphocyte Proliferation Test (LPT), is used to identify persons at riskof developing Chronic Beryllium Disease. The LPT examines how the white blood cells in ourbodies—lymphocytes—react to beryllium.

Step 1: Blood samples are drawn at clinics across the U.S. and shipped overnight to the ORISE Lab.

Step 2: Blood is layered onto a separation medium and spun in a centrifuge.

Step 3: Centrifuging the blood with density gradient medium separates blood components into layers. An opaque, cloudy layer containing lymphocytes is removed to use in the test.

Step 4: Saline is added to the lymphocytes and centrifuged twice to wash the cells.

Step 5: After the second wash, a cell count is prepared to determine the number of lymphocytes in the specimen.

Step 6: A hematology analyzer is used to count the number of cells in the sample.

Step 7: Lymphocytes combined with media and serum are placed in a 96-well culture plate containing beryllium and controls.

Step 8: The plates spend five to seven days in an incubator set at body temperature so the lymphocytes can grow.

Step 9: Tritiated thymidine, a radioactive marker, is added to the culture.

Step 10: The samples are drawn onto a filter plate.

Step 11: The amount of tritium on the filter paper is read by a liquid scintillation counter. The amount of tritium incorporated by the sample is proportional to the amount of cell proliferation.

Step 12: A technologist analyzes data, comparing cells grown in unstimulated wells and cells grown in beryllium-stimulated wells. The results are then sent to the person’s physician for evaluation.

Medical screenings offered through extensive nationwide network of clinics

When DOE sought an entity to provide medical screening for former employees of companies which supplied beryllium to DOE, the agency selected ORISE to manage the program. For these employees of beryllium producers no longer in business, ORISE administers a short health questionnaire and a blood test known as the beryllium lymphocyte proliferation test (BeLPT) to determine if a worker has been sensitized to the metal, and can recommend if he or she needs to be evaluated further for chronic beryllium disease (CBD).

If a worker has at least one abnormal BeLPT, he or she is referred for further evaluation through the Energy Employees Occupational Illness Compensation Program, which is administered by the U.S. Department of Labor.

DOE beryllium vendor companies that have closed:

  • American Beryllium Company (Bradenton, Florida)
  • Atomics International (all locations)
  • Nuclear Metals, Inc. (all locations)
  • Beryllium Corporation of America (all locations)
  • Nuclear Materials and Equipment Corporation (all locations)
  • Connecticut Aircraft Nuclear Engine Laboratory (Middletown, Connecticut)
  • Machlett Laboratories (Springdale, Connecticut)
  • Gerity-Michigan Corporation (Adrian, Michigan)
  • Revere Copper and Brass (Detroit, Michigan)
  • Wolverine Tube Division (Detroit, Michigan)
  • National Beryllia (Haskell, New Jersey)
  • U.S. Pipe and Foundry (Burlington, New Jersey)
  • United Lead Co. (Middlesex, New Jersey)
  • General Astrometals (Yonkers, New York)
  • Radium Chemical Company (New York, New York)
  • Sylvania Corning Nuclear Corporation - Bayside Lab (Bayside, New York)
  • Beryllium Metals and Chemical Corporation (Bessemer City, North Carolina)
  • Clifton Products Company (Painesville, Ohio)
  • Aeroprojects, Inc. (Westchester, Pennsylvania)
  • Foote Mineral Company (East Whiteland Township, Pennsylvania)
  • McDanel Refractory Company (Beaver Falls, Pennsylvania)
  • Vitro Manufacturing (Canonsburg, Pennsylvania)
  • Vitro Corporation of America (Oak Ridge, Tennessee)
Laboratory technician performing beryllium lymphocyte proliferation test

New beryllium lymphocyte proliferation test specification released

ORISE assisted DOE in revising and updating the specification for the performance of the beryllium lymphocyte proliferation test (BeLPT), a test used across the complex to determine if a worker is exhibiting biological signs of being sensitized to beryllium. The test is the first step in establishing whether a worker may be at increased risk for developing chronic beryllium disease, which is a lung disease associated with inhalation of beryllium dust or fumes.

The updated specification is quite similar to the previous version, released in 2001, but includes references to newer equipment and revised statistical analyses. DOE requires this updated specification to be used in all contracts with laboratories, like the ORISE Beryllium laboratory, for the purchase of BeLPT services.